Frequently Asked Questions about ANI Pharmaceuticals, Inc. (ANIP)

Name: ANI Pharmaceuticals, Inc. (ANIP) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does ANI Pharmaceuticals, Inc. (ANIP) do?

Accepted Answer

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. ...

Question 2

Is ANI Pharmaceuticals, Inc. (ANIP) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of ANIP reveals an Altman Z-Score of 2.40 and a Piotroski F-Score of 7/9. These metrics, combined with its 5-year revenue trend ($0.88B most recent), help investors decide if ANIP fits their risk profile.

Question 3

What is the current P/E ratio for ANIP?

Accepted Answer

As of the latest trading session, ANI Pharmaceuticals, Inc. (ANIP) has a trailing P/E ratio of 21.01.

Question 4

Who is the CEO of ANI Pharmaceuticals, Inc.?

Accepted Answer

The current Chief Executive Officer of ANI Pharmaceuticals, Inc. is Nikhil Lalwani.

Question 5

What was ANIP's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, ANI Pharmaceuticals, Inc. reported annual revenues of $0.88B (2025), $0.61B (2024), $0.49B (2023), $0.32B (2022), $0.22B (2021) respectively.

Question 6

Does ANIP pay a dividend?

Accepted Answer

ANI Pharmaceuticals, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does ANIP have?

Accepted Answer

In its latest reporting period, ANI Pharmaceuticals, Inc. generated $0.17B in Free Cash Flow against a total debt load of $0.33B.

Question 8

What is the Price-to-Book (P/B) ratio of ANI Pharmaceuticals, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for ANI Pharmaceuticals, Inc. (ANIP) is currently 2.95.

Question 9

What is the Price-to-Sales (P/S) ratio of ANIP?

Accepted Answer

Based on trailing twelve-month data, ANI Pharmaceuticals, Inc. (ANIP) trades at a Price-to-Sales (P/S) ratio of 2.02.

Question 10

What is ANI Pharmaceuticals, Inc.'s Return on Equity (ROE)?

Accepted Answer

ANI Pharmaceuticals, Inc. (ANIP) has a Return on Equity (ROE) of 15.55%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	883.4M	450.6M	81.2M	78.3M	3.50
2024-12	614.4M	364.2M	584K	-18.5M	-1.04
2023-12	486.8M	305.3M	47M	18.8M	0.95
2022-12	316.4M	177.6M	-35.3M	-47.9M	-3.05
2021-12	216.1M	115.5M	-39.8M	-42.6M	-3.40

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	883.4M	450.6M	81.2M	78.3M	3.50
2024-12	614.4M	364.2M	584K	-18.5M	-1.04
2023-12	486.8M	305.3M	47M	18.8M	0.95
2022-12	316.4M	177.6M	-35.3M	-47.9M	-3.05
2021-12	216.1M	115.5M	-39.8M	-42.6M	-3.40